Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jun 05, 2024 7:51pm
134 Views
Post# 36074250

RE:Very I last few weeks, months

RE:Very I last few weeks, monthsONC can say when the meeting date is Canaduh... it's 75 days from the date of receipt of the submission... it's very clear for Type C meeting... The meeting may not even be in person, FDA may just send responses to ONC... that's quite normal too. If FDA disagrees with the questions asked, then it's more likely that ONC will meet with them on the "meeting date".

Great that Roche is involved with Goblet...  BUt you should also recall Matt Coffey on record as saying, Roche ONLY needed the Aware-1 data to pull the trigger... 

He was careful enough not to say what pulling the trigger meant, but one would assume on a deal... and yet... of course he was also on record stating that Aware-1 would take a FEW months. The pps pumped in anticipation of news from this trial in early 2020... ONCY would have known that the trial was taking longer, but in their Dec 2019 slidedeck, they maintained their early Q1 data stance...

How's that for misleading investors?

You're right about finding a partner to run phase III or buy the company... Matt has just about run out of excuses on what direction mBC is heading.. The study protocol includes patient follow up to 2 years, and as per Clinical Trials.Gov, the trial completion date is July 2024. So, given the few patients still living, it should take no more than a few hours/days to complete the stats. I don't understand why ONC will wait till later in year to release results... or are they delaying because they still cannot find a partner.?

Every month is money burned... I want management to start providing some meat to the bones of this carcass. No more delays... a deal please Matt... 


<< Previous
Bullboard Posts
Next >>